There are several mechanisms to explain why metastatic tumors become more aggressive including one that postulates that the transition from classical estrogenic signaling of ER+ breast cancer to a growth factor signaling pathway facilitates the observed aggressiveness at metastatic sites. This evidence concerns the gene ESR1 and breast cancer.